Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Cinzia Pellizzoni"'
Autor:
Angela Scaburri, Cinzia Pellizzoni, Guido Kroemer, Bernard Laffranchi, Rastilav Balheda, Christophe Massard, Jean-Charles Soria, Chris Twelves, Jean-Pierre Armand, M. A. Pacciarini, A Proctor, D. Alan Anthoney
Publikováno v:
Cell Cycle. 10:963-970
PHA-793887 is an inhibitor of multiple cyclin dependent kinases (CDK) with activity against CDK2, CDK1 and CDK4. The primary objectives of this first in man study were to determine the dose limiting toxicities (DLTs), maximum tolerated dose (MTD) and
Autor:
Monica Simeoni, Massimiliano Germani, Giuseppe De Nicolao, Enrico Pesenti, Francesco Fiorentini, Maurizio Rocchetti, Cinzia Pellizzoni, Paola Zugnoni, Italo Poggesi
Publikováno v:
Basic Toxicology. 96:265-268
The in vivo evaluation of the antitumour effect using xenografted mice is a fundamental step in the preclinical development process of oncology drugs. In this type of experiments tumour cells from immortalized human cell lines are inoculated in athym
Autor:
Wilma Pastori, Simona Bindi, Daniele Casero, Marina Ciomei, Sabrina Cribioli, Nadia Amboldi, Cinzia Pellizzoni, Paola Gnocchi, Nilla Avanzi, Daniele Donati, Elena Ardini, Giulia Canevari, Gemma Texido, Arturo Galvani, Marcella Nesi, Maria Gabriella Brasca, Eduard R. Felder, Antonella Isacchi, Cinzia Cristiani, Roberta Ceruti, Veronica Patton
Publikováno v:
Molecular Cancer Therapeutics. 14:A179-A179
The Janus Kinases (JAK1, JAK2, JAK3, TYK2) are non-receptor tyrosine kinases that play important roles in hematopoiesis and immune response. In particular, gene ablation of JAK1 or JAK2 in the mouse is incompatible with life, due to neurological defe
Autor:
William Kevin, Kelly, Andrew X, Zhu, Howard, Scher, Tracey, Curley, Mary, Fallon, Susan, Slovin, Lawrence, Schwartz, Steve, Larson, William, Tong, Beryl, Hartley-Asp, Cinzia, Pellizzoni, Maurizio, Rocchetti
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 9(6)
The purpose is to determine a safe weekly dose of i.v. estramustine phosphate (EMP) to combine with weekly paclitaxel and monthly carboplatin in patients with advanced prostate cancer.Patients with advanced prostate cancer (castrate and noncastrate)
Autor:
E. Frigerio, Cinzia Pellizzoni, Maria Grazia Castelli, Paola Tocchetti, Philippe Dostert, Giannantonio Brianceschi, Margherita Strolin Benedetti
Publikováno v:
Chirality. 7(4)
Reboxetine, (RS)-2-[(RS)-α-(2-ethoxyphenoxy)benzyl]morpholine methanesulphonate, is a racemic compound and consists of a mixture of the (R,R)- and (S,S)-enantiomers. In this study, brain and plasma levels of both enantiomers were determined in mice